Subscribe To
Greenwich lifesciences reveals 5-year data for gp2 immunotherapy in breast cancer settings
Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a stand...
December 9, 2021, 1:19 pm
Novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings
Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic br...
December 8, 2021, 1:27 pm
Novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings
Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic br...
December 8, 2021, 1:27 pm
Novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings
Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic br...
December 8, 2021, 1:27 pm
1 cancer stock on buyout watch in 2022
Cardiff Oncology is a prime takeover target heading into 2022....
November 21, 2021, 9:45 am
1 cancer stock on buyout watch in 2022
Cardiff Oncology is a prime takeover target heading into 2022....
November 21, 2021, 9:45 am
1 cancer stock on buyout watch in 2022
Cardiff Oncology is a prime takeover target heading into 2022....
November 21, 2021, 9:45 am
Mersana highlights new preclinical data for xmt-2056 cancer settings
Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual Internati...
October 8, 2021, 12:52 pm
Mersana highlights new preclinical data for xmt-2056 cancer settings
Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual Internati...
October 8, 2021, 12:52 pm
Mersana highlights new preclinical data for xmt-2056 cancer settings
Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual Internati...
October 8, 2021, 12:52 pm